Sign in to view content

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration

David A. Eichenbaum, MD, FASRS

Video
Published 2018

Related

What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
A Randomized Trial of Intravitreous Anti-VEGF for Prevention of Vision Threatening Complications of Diabetic Retinopathy (Protocol W)
Raj K. Maturi, MD
Annual Meeting Talks
2021
Suprachoroidal Triamcinolone Acetonide with and without Intravitreal Aflibercept for Diabetic Macular Edema: Results of the 6-Month Prospective, Phase 1/2 Hulk Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2017

Category: AMD-Neovascular

Anti-VEGF

See more